By expressing two CXCR4 mutated variants in AML cells with disrupted endogenous Cxcr4, we could show that CXCR4 signaling, but not CXCL12 binding, is essential for MLL-AF9 leukemia cells in vivo. This evidence concerns the gene CXCL12 and acute myeloid leukemia.